SCHEMBL4316639

SCHEMBL4316639

Fc1cc(-c2cc(-c3cnccn3)no2)cc(F)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
ALOX5AP P20292 2/20 0.36
FEN1 P39748 2/20 0.36
CYP3A4 P08684 8/20 0.35
CYP2C9 P11712 8/20 0.35
CYP2C19 P33261 8/20 0.35
CYP2D6 P10635 7/20 0.35
PKM P14618 1/20 0.35
CYP1A2 P05177 8/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PIM1 P11309 1/20 0.33
SCD5 Q86SK9 1/20 0.32
S1PR1 P21453 1/20 0.32
CXCR1 P25024 1/20 0.32
PIK3CD O00329 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CB P42338 1/20 0.31
PI4KA P42356 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4318598 0.85 CHRNB2 (0.43) GRM5NPC1RAB9AALOX5APFEN1
SCHEMBL4325938 0.82 CYP3A4 (0.51) GRM5NPC1RAB9ACYP3A4CYP2C9
SCHEMBL4315678 0.78 CYP1A2 (0.54) GRM5NPC1RAB9ACYP3A4CYP2C9
SCHEMBL18812089 0.78 ALOX5AP (0.43) GRM5NPC1RAB9AALOX5APFEN1
SCHEMBL4322362 0.78 RAB9A (0.61) NPC1RAB9ACYP3A4CYP2C9CYP2C19
SCHEMBL4315894 0.78 CYP2C19 (0.51) NPC1RAB9ACYP3A4CYP2C9CYP2C19
SCHEMBL4319862 0.77 CYP2C9 (0.52) NPC1RAB9ACYP3A4CYP2C9CYP2C19
SCHEMBL4321598 0.76 NPC1 (0.41) NPC1RAB9ACYP3A4CYP2C9CYP2C19
SCHEMBL4324727 0.76 GRM5 (0.41) GRM5NPC1RAB9ACYP3A4CYP2C9
SCHEMBL4321635 0.74 NPC1 (0.39) NPC1RAB9ACYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US claimed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO claimed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US claimed
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO disclosed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof XDH, PRDX5, CYP4X1 GRM5 1012/4885NPC1 837/4885RAB9A 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.